PEG drugs: An overview

Journal of Controlled Release

Volumn 74, Issue 1-3, 2001, Pages 159-171

  Greenwald, R B ^a  

^a Enzon Incorporated   (United States)

Author keywords

Anticancer drug conjugates; Camptothecin; EPR effect; Paclitaxel; Poly(ethylene glycol); Prodrugs

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE MACROGOL; CAMPTOTHECIN MACROGOL; CREMOPHOR; DAUNORUBICIN MACROGOL; GLYCINE MACROGOL; MACROGOL; PACLITAXEL; PACLITAXEL MACROGOL; PRODRUG; PROTHECAN; TOPOTECAN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; HUMAN; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; TUMOR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; EXCIPIENTS; HUMANS; MICE; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS;

EID: 0035816168     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(01)00331-5     Document Type: Conference Paper

References (55)

1. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol
2. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-modified asparaginase conjugates
3. Branched poly(ethylene glycol) linkers
4. A branched monomethoxypoly (ethylene glycol) for protein modification
5. On the suitability of urethane bonds between the carrier and the drug moiety in poly(ethylene glycol)-based oligomeric prodrugs
6. Preparation and properties of monomethoxy poly(ethylene glycol) doxorubicin conjugates linked by an amino acid or a peptide as spacer
7. Poly (ethylene glycol) with reactive end groups: I. Modification of proteins
8. Functionalized poly (ethylene glycol) for preparation of biologically relevant conjugates
9. Attachment of drugs to polyethylene glycols
10. Highly water soluble taxol derivatives: 7-Polyethylene glycol carbamates and carbonates
11. PEG modified anticancer drugs: Synthesis and biological activity
12. Highly water soluble taxol derivatives: 2-Polyethylene glycol esters as potential prodrugs
13. Drug delivery systems: Water soluble taxol 2-poly (ethylene glycol) ester prodrugs-design and in vivo effectiveness
14. Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice
15. w) of N-(2-hydroxypropyl) methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats
16. Prodrugs, do they have advantages in clinical practice?
17. Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug carrier
18. A novel connector linkage applicable in prodrug design
19. The double prodrug concept and its applications
20. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): A water-soluble prodrug
21. Camptothecin-20-PEG ester transport forms: The effect of spacer groups on antitumor activity
22. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity
23. Modified taxols, 6. Preparation of water-soluble prodrugs of taxol
24. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity
25. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy
26. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo
27. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues
28. Targetable drug carriers: Present status and a future perspective
29. Camptothecins: From bench research to hospital wards
30. Water-soluble camptothecin derivatives
31. Camptothecin and taxol: Discovery to clinic: Thirteenth Bruce F. Cain memorial award lecture
32. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs
33. Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms
34. Camptothecin delivery systems: The antitumor activity of a camptothecin-20-O-polyethylene glycol ester transport form
35. 20-O-acylcamptothecin derivatives: Evidence for lactone stabilization
36. Camptothecin-20-PEG ester transport forms: The effect of spacer groups on antitumor activity
37. Camptothecin delivery systems: The utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs
38. Camptothecin delivery systems: Enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker
39. The design of selectively activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies
40. 1,4- and 1,6-eliminations from hydroxy and amino-substituted benzyl systems: Chemical and biochemical applications
41. Novel chemical approaches in prodrug design
42. Drug delivery systems employing 1,4-or 1,6-elimination: Poly (ethylene glycol) prodrugs of amine containing compounds
43. Prodrug strategies based on intramolecular cyclization reactions
44. Design of intramolecularly activated prodrugs
45. Prodrug approaches to the improved delivery of peptide prodrugs
46. Drug delivery systems based on trimethyl lock lactonization: Poly (ethylene glycol) prodrugs of amine containing compounds
47. Alkaline hydrolysis of some carbamic acid esters
48. The mechanism of the alkaline hydrolysis of p-nitrophenyl N-methylcarbamate
49. Drug delivery systems employing 1,6-elimination: Releasable poly-(ethylene glycol) conjugates of proteins
50. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-a: A novel polymer-conjugation technique with a reversible amino-protective reagent
51. Detection and characterization of antibodies to PEG-IFN-α2b using surface plasmon resonance
52. Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins
53. PEG thiazolidine-2-thione, a novel reagent for facile protein modification: Conjugation of bovine hemoglobin